Study guide

12.3 Peripartum Substance Overdose, Opioid Toxicity & Naloxone Administration

C-OBE Obstetric Emergencies Exam

Track your progress as you read

Finished sections get a check mark.

1 Chapter 1: Maternal Assessment, Risk Stratification & Early Warning Systems

1.1 Pre-Existing Medical, Surgical & Obstetric Comorbidities in Emergency Risk Stratification 1.2 Dynamic Antepartum & Intrapartum Risk Assessment 1.3 Maternal Early Warning Systems (MEWS/MEWT) & Critical Triage Physical Assessment 1.4 Alliance for Innovation on Maternal Health (AIM) Safety Bundles & Emergency Readiness

2 Chapter 2: Obstetric Hemorrhage — Etiology, Assessment & Uterotonics

2.1 Postpartum Hemorrhage Etiology (4 T's) & Quantitative Blood Loss (QBL) 2.2 Uterotonic Pharmacology & Stepwise Administration Protocols 2.3 Tranexamic Acid (TXA) Protocols & Hemorrhage Timing

3 Chapter 3: Obstetric Hemorrhage — Mechanical Interventions, Placental Disorders & Transfusion

3.1 Intrauterine Tamponade Balloons, Compression Sutures & Surgical Hemostasis 3.2 Ectopic Pregnancy, Placenta Previa, Accreta Spectrum (PAS), Abruption & Vasa Previa 3.3 Obstetric DIC, Coagulopathy & Massive Transfusion Protocol (MTP)

4 Chapter 4: Hypertensive Disorders of Pregnancy & Preeclampsia with Severe Features

4.1 Classification & Spectrum of Hypertensive Disorders of Pregnancy 4.2 Preeclampsia with Severe Features: Pathophysiology & End-Organ Damage 4.3 Diagnostic Evaluation, Laboratory Triggers & Fetal Surveillance in Preeclampsia

5 Chapter 5: Hypertensive Crisis, Eclampsia & Magnesium Sulfate Therapy

5.1 Acute Severe Hypertension & First-Line Antihypertensive Protocols 5.2 Eclampsia Recognition, Seizure Management & Airway Protection 5.3 Magnesium Sulfate Neuroprotection/Seizure Prophylaxis Protocols, Monitoring & Toxicity Reversal 5.4 HELLP Syndrome & Hepatic Crisis Management

6 Chapter 6: Maternal Resuscitation, Cardiac Arrest & Perimortem Cesarean

6.1 Maternal ACLS Modifications & Cardiopulmonary Resuscitation Physiology 6.2 Etiologies of Maternal Arrest & Structured Emergency Response 6.3 Perimortem Cesarean Delivery (PMCD / Resuscitative Hysterotomy)

7 Chapter 7: Amniotic Fluid Embolism & Maternal Shock States

7.1 Amniotic Fluid Embolism (AFE): Pathophysiology & Clinical Presentation 7.2 A-OK Protocol, Hemodynamic Support & Critical Care in AFE 7.3 Maternal Shock States: Hemorrhagic, Distributive, Cardiogenic & Obstructive

8 Chapter 8: Acute Intrapartum Delivery Emergencies

8.1 Shoulder Dystocia: Recognition, Timing & Primary HELPERR Sequence 8.2 Advanced Shoulder Dystocia Maneuvers & Neonatal Brachial Plexus Injury Prevention 8.3 Umbilical Cord Prolapse Recognition & Emergent Decompression Protocols

9 Chapter 9: Uterine Inversion, Malpresentation & Obstetric Trauma

9.1 Acute Uterine Inversion: Recognition, Tocolysis & Manual/Surgical Reduction 9.2 Emergency Vaginal Breech Extraction & Head Entrapment Maneuvers 9.3 Maternal Trauma: Primary/Secondary Survey, Placental Abruption & Fetomaternal Hemorrhage

10 Chapter 10: Maternal Sepsis, Intraamniotic Infection & Severe Infections

10.1 Maternal Sepsis: Physiological Criteria, S.O.S. Score & omSOFA 10.2 The Maternal Sepsis Hour-1 Bundle & Fluid/Vasopressor Optimization 10.3 Intraamniotic Infection (Triple I / Chorioamnionitis) & Severe Endometritis 10.4 Severe Pyelonephritis, Maternal Pneumonia & Severe Peripartum Infections

11 Chapter 11: Endocrine, Cardiovascular, Respiratory & Neurologic Emergencies

11.1 Diabetic Ketoacidosis (DKA), Maternal Hypoglycemia & Endocrine Resuscitation in Pregnancy 11.2 Peripartum Cardiomyopathy (PPCM), Acute Heart Failure, Acute Coronary Syndromes & Maternal Arrhythmias 11.3 Status Asthmaticus, Pulmonary Edema & ARDS in Pregnancy 11.4 Status Epilepticus, Acute Stroke & Cerebral Venous Sinus Thrombosis (CVST)

12 Chapter 12: Thromboembolism, Hepatorenal Disorders & Toxicologic Emergencies

12.1 Venous Thromboembolism (DVT/PE) Diagnosis, Treatment & Peripartum Anticoagulation 12.2 Acute Fatty Liver of Pregnancy (AFLP / Swansea Criteria) & Acute Kidney Injury 12.3 Peripartum Substance Overdose, Opioid Toxicity & Naloxone Administration

13 Chapter 13: Obstetric Anesthesia Emergencies & Critical Complications

13.1 High Spinal / Total Spinal Anesthesia & Aspiration Pneumonitis 13.2 Local Anesthetic Systemic Toxicity (LAST) & 20% Lipid Emulsion Rescue Protocol 13.3 Post-Dural Puncture Headache (PDPH), Epidural Hematoma & Abscess 13.4 Malignant Hyperthermia in Obstetric Anesthesia & Dantrolene Protocol

14 Chapter 14: Professional Practice, Team Communication, Debriefing & Health Equity

14.1 Crisis Resource Management (CRM), TeamSTEPPS & Structured Communication 14.2 Multidisciplinary Emergency Debriefing, Morbidity & Mortality, and Systems Learning 14.3 Perinatal Racial/Ethnic Disparities, Implicit Bias Mitigation & Respectful Maternity Care 14.4 Legal, Ethical, Documentation & EMTALA Standards in Obstetric Emergencies

12.3 Peripartum Substance Overdose, Opioid Toxicity & Naloxone Administration

Key Takeaways Explain This Topic AI

Acute opioid overdose in pregnancy presents with the classic toxidrome of respiratory depression (apnea or RR <8-10 bpm), pinpoint pupils (miosis), and central nervous system depression; severe maternal hypoxia rapidly leads to acute fetal hypoxemia, non-reassuring fetal heart rate patterns (prolonged bradycardia, loss of variability), and intrauterine fetal demise.

In opioid-dependent pregnant individuals, naloxone must be titrated in small intravenous increments (0.04 to 0.1 mg IV push every 2 to 3 minutes) with the goal of restoring adequate spontaneous maternal ventilation (RR >10-12 bpm, SpO2 >92%), rather than full consciousness, to prevent precipitating acute severe opioid withdrawal, which causes severe uterine tetany, placental abruption, and fetal death.

Synthetic opioids (e.g., fentanyl, methadone) have prolonged or unpredictable durations of action compared to naloxone (half-life 30-90 minutes); recurrent respiratory arrest occurs in up to 50% of cases, requiring continuous IV naloxone infusions and a mandatory 4- to 24-hour observation period.

Stimulant toxicity (cocaine and methamphetamine) triggers a life-threatening hyperadrenergic crisis (severe hypertension, hyperthermia, tachycardia, placental abruption, and aortic dissection); intravenous benzodiazepines are the first-line treatment of choice, whereas pure beta-blockers are strictly contraindicated due to catastrophic unopposed alpha-adrenergic vasoconstriction.

Carbon monoxide (CO) poisoning produces severe fetal hypoxia because fetal hemoglobin (HbF) binds CO with greater affinity than maternal hemoglobin (HbA) and eliminates it much slower; Hyperbaric Oxygen (HBO) therapy is fetal-protective and specifically indicated in pregnancy for maternal carboxyhemoglobin (COHb) levels >15% to 20%, loss of consciousness, or any signs of fetal distress.

Last updated: August 2026

Peripartum Substance Overdose, Opioid Toxicity & Naloxone Administration

Substance use disorders and acute accidental toxicologic overdoses are leading contributors to pregnancy-associated mortality in the United States and globally. The physiological adaptations of pregnancy—such as expanded plasma volume, altered hepatic cytochrome P450 enzyme activity, and diminished respiratory reserve—significantly modify xenobiotic toxicity and complicate emergency resuscitation.

  • 1. Opioid Overdose & Toxicity in Pregnancy
  • The Opioid Toxidrome

Opioids (including heroin, fentanyl, oxycodone, morphine, methadone, and buprenorphine) stimulate central mu-opioid receptors, depressing the pontine and medullary respiratory control centers. The classic opioid triad comprises:

Severe Respiratory Depression: Bradypnea (respiratory rate <8 to 10 breaths/min), shallow hypopnea, or absolute apnea.

Miosis (Pinpoint Pupils): Pupillary constriction (though severe hypoxia, tramadol, meperidine, or co-ingested stimulants may cause normal or dilated pupils).

Central Nervous System Depression: Stupor, unresponsiveness, or coma with loss of protective airway reflexes, flaccidity, hyporeflexia, bradycardia, and hypothermia.

Maternal-Fetal Pathophysiology

Maternal respiratory depression leads rapidly to maternal hypercapnia and severe arterial hypoxemia. Because the fetus relies entirely on maternal oxygen delivery across the placental barrier, maternal hypoxemia rapidly provokes profound fetal hypoxemia, severe metabolic acidosis, persistent late decelerations, prolonged fetal bradycardia, loss of FHR variability, and intrauterine fetal demise (IUFD) .

2. Emergency Naloxone Administration Protocol in Pregnancy

Naloxone is a pure, competitive mu-, kappa-, and delta-opioid receptor antagonist that rapidly reverses opioid-induced respiratory and central nervous system depression. +---------------------------------------------------------------------------------------------------+

  • | CRITICAL PREGNANCY NALOXONE PRINCIPLES |
  • | |
  • | • PRIMARY RESUSCITATIVE GOAL: |
  • | - The sole therapeutic endpoint of naloxone in pregnancy is to **restore adequate spontaneous |
  • | maternal ventilation** (respiratory rate 10 to 12 breaths/min, SpO2 >=92% to 95%), thereby |
  • | restoring fetal oxygenation. |
  • | - The goal is NOT to awaken the patient or restore full alertness! |
  • | |
  • | • THE DANGER OF ACUTE PRECIPITATED WITHDRAWAL IN PREGNANCY: |
  • | - In patients with chronic physical opioid dependence, administering a large bolus of naloxone |
  • | (e.g., 2.0 to 4.0 mg IV) precipitates sudden, severe acute opioid withdrawal. |
  • | - Acute withdrawal triggers a massive sympathetic catecholamine surge, causing: |
  • | 1. Severe uterine hypertonus and tetanic contractions. |
  • | 2. Placental abruption (abruptio placentae). |
  • | 3. Acute uteroplacental hypoperfusion and severe fetal distress / demise. |
  • | 4. Precipitous preterm labor and delivery. |
  • | |
  • | • TITRATED DOSING REGIMEN: |
  • | - Step 1: Immediately support airway and provide Bag-Valve-Mask (BVM) ventilation with 100% O2.|
  • | - Step 2: In a breathing patient with hypoventilation or suspected dependence, administer |
  • | **Naloxone 0.04 to 0.1 mg IV push**. |
  • | - Step 3: Reassess ventilation after 2 to 3 minutes. If respiratory depression persists, |
  • | titrate upward in increments: **0.1 mg -> 0.2 mg -> 0.4 mg IV** every 2 to 3 minutes. |
  • | - Step 4: If in cardiac arrest or severe unresponsiveness with no IV access, administer |
  • | **Naloxone 2 to 4 mg IN (intranasal) or 0.4 to 2 mg IM** while continuing ACLS. |
  • +---------------------------------------------------------------------------------------------------+
  • Pharmacokinetics & Recurrent Toxicity

Duration of Action Disparity: Naloxone has an effective serum half-life of only 30 to 90 minutes . Conversely, long-acting synthetic opioids (fentanyl, methadone, extended-release oxycodone) have half-lives extending from 4 to 36+ hours .

Recurrent Resedation: As naloxone is metabolized and clears opioid receptors, patients frequently lapse back into severe respiratory arrest ("renarcotization").

Continuous Infusion Protocol: If multiple boluses are required, initiate a continuous intravenous infusion: calculate two-thirds (2/3) of the total successful bolus dose per hour in crystalloid.

Mandatory Observation Period: Observe for a minimum of 4 to 6 hours for short-acting opioids and 12 to 24 hours for long-acting or extended-release opioids (e.g., methadone). +---------------------------------------------------------------------------------------------------+

  • | NEONATAL RESUSCITATION PRECAUTION (NO NALOXONE) |
  • | |
  • | • CONTRAINDICATION IN NEWBORNS WITH MATERNAL OPIOID DEPENDENCE: |
  • | - Naloxone is **STRICTLY CONTRAINDICATED in the immediate resuscitation of the newborn** when |
  • | maternal chronic opioid dependence is known or suspected. |
  • | - Direct neonatal naloxone administration triggers severe neonatal seizures, acute pulmonary |
  • | edema, cardiovascular collapse, and catastrophic withdrawal. |
  • | - Neonatal Resuscitation Program (NRP) Protocol: Establish effective Positive Pressure |
  • | Ventilation (PPV) with room air/oxygen and airway support; allow the neonate to metabolize |
  • | the opioid gradually while monitoring for Neonatal Abstinence Syndrome (NAS/NOWS). |
  • +---------------------------------------------------------------------------------------------------+
  • 3. Stimulant Toxicity: Cocaine & Methamphetamine
  • Pathophysiology & The Sympathomimetic Toxidrome

Cocaine blocks the presynaptic reuptake of norepinephrine, epinephrine, dopamine, and serotonin, and blocks myocardial fast sodium channels (local anesthetic cardiotoxicity). Methamphetamine promotes excessive presynaptic release and inhibits monoamine reuptake and monoamine oxidase breakdown. +---------------------------------------------------------------------------------------------------+

  • | SYMPATHOMIMETIC TOXIDROME & OBSTETRIC CRISES |
  • | |
  • | • MATERNAL CLINICAL FEATURES: |
  • | - Severe Hypertension (SBP >180-200 mmHg), Tachycardia (>120-160 bpm), Tachypnea. |
  • | - Severe Hyperthermia (core temperature >39-40°C / 102.2-104°F) secondary to motor agitation |
  • | and cutaneous vasoconstriction. |
  • | - Diaphoresis (distinguishes sympathomimetic toxicity from anticholinergic toxidrome!). |
  • | - Mydriasis (dilated reactive pupils), psychomotor agitation, paranoia, hallucinations, tremors|
  • | - Cardiac dysrhythmias, coronary vasospasm, acute myocardial infarction, aortic dissection. |
  • | |
  • | • CATASTROPHIC OBSTETRIC COMPLICATIONS: |
  • | 1. Acute Placental Abruption (Abruptio Placentae): Intense vasospasm of maternal spiral |
  • | arterioles and acute shearing pressures cause immediate decidual necrosis and separation. |
  • | 2. Acute Uteroplacental Insufficiency & Fetal Hypoxia: Massive uterine artery vasoconstriction.|
  • | 3. Spontaneous Uterine Rupture, Preterm Labor, and Precipitous Delivery. |
  • +---------------------------------------------------------------------------------------------------+
  • Emergency Pharmacotherapy for Stimulant Crisis

Therapeutic Class Recommended Agents & Regimens Clinical Rationale & Action

First-Line Pharmacotherapy Benzodiazepines ; • Lorazepam 2 to 4 mg IV q5–10 min; • Diazepam 5 to 10 mg IV q5–10 min Treatment of Choice. Enhances central GABA transmission, blunting central sympathetic outflow, reducing agitation, controlling hypertension/tachycardia, and aborting seizures.

Persistent Severe Hypertension Nicardipine IV infusion (5–15 mg/h) OR Nitroglycerin IV (20–200 mcg/min) OR Hydralazine 5–10 mg IV Indicated if blood pressure remains dangerously elevated despite adequate benzodiazepine sedation. Induces direct arteriolar vasodilation.

Refractory Sympathetic Crisis Phentolamine (1–5 mg IV) OR Labetalol (10–20 mg IV slow push) Direct alpha-adrenergic receptor antagonist (Phentolamine) or combined alpha/beta blocker with predominant alpha effect (Labetalol).

STRICTLY CONTRAINDICATED Pure Beta-Blockers ; (Metoprolol, Atenolol, Propranolol, Esmolol) ABSOLUTELY CONTRAINDICATED! Causes unopposed alpha-adrenergic stimulation , triggering catastrophic paradoxical hypertension, lethal coronary vasospasm, and circulatory collapse. +---------------------------------------------------------------------------------------------------+

  • | HYPERTHERMIA MANAGEMENT IN STIMULANT OVERDOSE |
  • | |
  • | • Core temperature >39.0°C (102.2°F) carries extreme risk of maternal rhabdomyolysis, DIC, |
  • | renal failure, and fetal death. |
  • | • Immediate Interventions: |
  • | 1. Administer aggressive IV benzodiazepines to halt muscular shivering and agitation. |
  • | 2. Initiate rapid evaporative cooling: mist patient with lukewarm water while running fans. |
  • | 3. Apply ice packs to axillae, groin, and neck; infuse cold IV normal saline. |
  • | 4. Antipyretics (acetaminophen) are INEFFECTIVE because hyperthermia is caused by excessive |
  • | muscular heat generation, not a set-point shift in the hypothalamus. |
  • +---------------------------------------------------------------------------------------------------+
  • 4. Carbon Monoxide & Toxic Inhalants in Pregnancy
  • Carbon Monoxide (CO) Pathophysiology in Pregnancy

Carbon monoxide is a colorless, odorless gas that binds to hemoglobin with an affinity 200 to 250 times greater than oxygen , forming carboxyhemoglobin (COHb) and shifting the oxyhemoglobin dissociation curve to the left (Haldane effect), which impairs peripheral oxygen offloading. +---------------------------------------------------------------------------------------------------+

  • | FETAL VULNERABILITY TO CARBON MONOXIDE |
  • | |
  • | • GREATER AFFINITY OF FETAL HEMOGLOBIN (HbF): |
  • | - Fetal hemoglobin binds carbon monoxide even more avidly than adult maternal hemoglobin. |
  • | - Fetal COHb levels consistently equilibrate **10% to 15% HIGHER than maternal COHb levels**. |
  • | |
  • | • DELAYED FETAL CLEARANCE: |
  • | - The half-life of COHb in maternal circulation breathing room air is ~300 minutes; in the |
  • | fetus, COHb half-life is **up to 7 hours (420 minutes)** due to slow transplacental diffusion.|
  • | - Severe fetal hypoxia, teratogenicity (anatomical limb/CNS defects in 1st trimester), or |
  • | fetal death can occur even when maternal symptoms are mild and maternal COHb is modest! |
  • +---------------------------------------------------------------------------------------------------+
  • Hyperbaric Oxygen (HBO) Therapy Indications

100% Normobaric Oxygen: Administer immediately via tight-fitting non-rebreather mask to all pregnant patients with suspected CO exposure (reduces maternal COHb half-life from 300 minutes to 60–90 minutes). Continue for at least 4 to 5 times longer than non-pregnant patients to ensure adequate fetal clearance.

Hyperbaric Oxygen (HBO, 2.5 to 3.0 ATA): Reduces COHb half-life to 20 to 30 minutes and rapidly delivers dissolved oxygen directly to maternal and fetal tissues. Pregnancy is NOT a contraindication; HBO is fetal-protective. +---------------------------------------------------------------------------------------------------+

  • | HBO INDICATIONS IN PREGNANCY (LOWER THRESHOLD) |
  • | |
  • | 1. Maternal Carboxyhemoglobin (COHb) Level >15% to 20% (vs. >25% in non-pregnant individuals). |
  • | 2. Any Maternal Loss of Consciousness, Syncope, or Altered Mental Status. |
  • | 3. Maternal Neurological Deficits, Seizures, or Coma. |
  • | 4. Maternal Cardiovascular Instability, Severe Acidosis, or Myocardial Ischemia. |
  • | 5. Any Evidence of Fetal Distress (Tachycardia, Late Decelerations, Absent Variability). |
  • +---------------------------------------------------------------------------------------------------+
  • Other Toxic Inhalants

Nitrous Oxide ("Whippets"): Chronic or acute heavy abuse inactivates cobalamin (Vitamin B12) by oxidizing cobalt, disabling methionine synthase and leading to severe hyperhomocysteinemia, subacute combined degeneration of the spinal cord (ataxia, paresthesias), and fetal neural tube defects or IUGR.

Volatile Hydrocarbons (Inhalants / Solvents): Induce "sudden sniffing death syndrome" via myocardial sensitization to endogenous catecholamines, triggering lethal ventricular fibrillation.

Loading diagram... Peripartum Toxicologic Emergencies Management Algorithm